The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications
小RNA衍生的tRNA在基因调控中的作用:机制和治疗应用
基本信息
- 批准号:9365781
- 负责人:
- 金额:$ 52.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntisense OligonucleotidesApoptosisBiogenesisCell DeathCell ProliferationCell SurvivalCellsCodeComplementDataDefectDoseGene ExpressionGene Expression RegulationGenesGeneticGenetic TranscriptionGenomeGoalsHigh-Throughput Nucleotide SequencingHumanImplantLeucineLiteratureLiverLiver neoplasmsMalignant NeoplasmsMammalian CellMammalsMeasuresMediatingMedicalMessenger RNAModelingModernizationMolecularMusOligonucleotidesOrganismPatientsPhenotypePlayPopulationPoriferaPrimary carcinoma of the liver cellsProcessProteinsRNARNA, Ribosomal, 18SRegulationRegulator GenesRegulatory PathwayRibosomal ProteinsRibosomesRoleSafetySignal TransductionSmall RNAStructureTestingTherapeuticTissuesTransfer RNATranslationsUntranslated RNAVariantXenograft procedureadeno-associated viral vectorbasecell growthclinical efficacydark matterdifferential expressionfallsgene therapyhuman diseasein vivoindividual patientknock-downmammalian genomemouse modelnew therapeutic targetnovelpre-clinicalresponsetherapeutic targettransgene expressiontumortumor growth
项目摘要
ABSTRACT
One of the most important concepts in modern genetics is the realization that over 90% of the mammalian
genome is transcribed into RNA. These non-protein coding RNAs have been described as the dark matter
of the genome as the function of most of these RNAs has yet to be determined. Just over 5 years ago, we
stumbled onto a novel set of tRNA derived small RNAs (tsRNAs). These tRNA derived fragments are also
commonly called trfRNAs, and were originally thought to represent degradation products. However, it is now
clear there are hundreds or perhaps thousands of different RNA fragments generated in mammalian cells
and there is increasing evidence that these are functionally important. As a group, they have been proposed
to regulate genes at many different levels. We plan to study the 3’tsRNAs (derived from the 3’ end of the
mature tRNA) currently the least well studied of the various types of fragments, and for which no definitive
function has yet to be described. We have established that one specific RNA, the 22nt CAG-Leucine
3’tsRNA when down regulated by the addition of antisense oligonucleotides in rapidly dividing cells inhibits
ribosome biogenesis by first limiting the translation of at least one ribosomal protein mRNA. This results in
rapid cellular apoptosis. In contrast, the addition of a 3’tsRNA mimic increases cellular proliferation and can
complement the ribosome biogenesis defects in cells. These data bring to light a previously unknown post-
transcriptional gene regulatory pathway. We plan to further explore the mechanism of how this specific
3’tsRNA-mediates translational gene regulation as well as use new high-throughput sequencing approaches
to identify and then test other 3’tsRNAs that may participate in similar types of gene regulation. Finally, we
propose to use gene therapy and oligonucleotide antisense delivery to pursue the therapeutic potential of
manipulating 3’tsRNAs in treating medical conditions that affect the liver. We believe unraveling the
molecular mechanism of this regulatory circuit is important both to further understand how genes are
regulated and will provide novel therapeutic targets.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark A Kay其他文献
AAV vectors and tumorigenicity
腺相关病毒载体与致瘤性
- DOI:
10.1038/nbt1007-1111 - 发表时间:
2007-10-01 - 期刊:
- 影响因子:41.700
- 作者:
Mark A Kay - 通讯作者:
Mark A Kay
RNA interference gene therapy: RNA interference gets infectious
RNA干扰基因疗法:RNA干扰具有传染性
- DOI:
10.1038/sj.gt.3302035 - 发表时间:
2003 - 期刊:
- 影响因子:5.1
- 作者:
Ap Mccaffrey;Mark A Kay;Anton P. McCaffrey;Mark A Kay - 通讯作者:
Mark A Kay
Mark A Kay的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark A Kay', 18)}}的其他基金
3' tsRNAs: biologic function and pre-clinical targeting for treating human disease
3 tsRNA:治疗人类疾病的生物学功能和临床前靶向
- 批准号:
10735190 - 财政年份:2023
- 资助金额:
$ 52.78万 - 项目类别:
The role of small RNA derived tRNAs in gene regulation: Mechanism and Therapeutic Applications
小RNA衍生的tRNA在基因调控中的作用:机制和治疗应用
- 批准号:
9763548 - 财政年份:2017
- 资助金额:
$ 52.78万 - 项目类别:
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries
使用复制病毒衣壳文库选择新的 rAAV 载体
- 批准号:
8861132 - 财政年份:2015
- 资助金额:
$ 52.78万 - 项目类别:
AAV capsid engineering for enhancing gene transfer
用于增强基因转移的 AAV 衣壳工程
- 批准号:
10574568 - 财政年份:2015
- 资助金额:
$ 52.78万 - 项目类别:
Selection of New rAAV Vectors Using Replicating Viral Capsids Libraries
使用复制病毒衣壳文库选择新的 rAAV 载体
- 批准号:
9022412 - 财政年份:2015
- 资助金额:
$ 52.78万 - 项目类别:
AAV capsid engineering for enhancing gene transfer
用于增强基因转移的 AAV 衣壳工程
- 批准号:
10352396 - 财政年份:2015
- 资助金额:
$ 52.78万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
8044028 - 财政年份:2009
- 资助金额:
$ 52.78万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
8230691 - 财政年份:2009
- 资助金额:
$ 52.78万 - 项目类别:
Molecular Evolution Strategies to Derive New Recombinant AAV Vectors
衍生新重组 AAV 载体的分子进化策略
- 批准号:
7654164 - 财政年份:2009
- 资助金额:
$ 52.78万 - 项目类别:
相似海外基金
Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels
开发反义寡核苷酸来调节γ纤维蛋白原水平
- 批准号:
10759950 - 财政年份:2023
- 资助金额:
$ 52.78万 - 项目类别:
Inducing H3F3A exon skipping with antisense oligonucleotides as an approach to treat diffuse intrinsic pontine glioma
用反义寡核苷酸诱导 H3F3A 外显子跳跃作为治疗弥漫性内源性脑桥胶质瘤的方法
- 批准号:
10677284 - 财政年份:2023
- 资助金额:
$ 52.78万 - 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
- 批准号:
10464020 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy
使用反义寡核苷酸促进成人海马神经发生作为阿尔茨海默氏病的治疗
- 批准号:
10484703 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Strategy for specific delivery of antisense oligonucleotides to T cells
将反义寡核苷酸特异性递送至 T 细胞的策略
- 批准号:
10547347 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10806783 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10689248 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Metabolism of Antisense Oligonucleotides and other Polyanions in Liver
反义寡核苷酸和其他聚阴离子在肝脏中的代谢
- 批准号:
10501862 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Inducing PKM splice-switching with antisense oligonucleotides as an approach to treat hepatocellular carcinoma
用反义寡核苷酸诱导 PKM 剪接转换作为治疗肝细胞癌的方法
- 批准号:
10623180 - 财政年份:2022
- 资助金额:
$ 52.78万 - 项目类别:
Identifying binding partners, biological substrates and antisense oligonucleotides regulating expression of short and long ACE2.
识别调节短和长 ACE2 表达的结合伴侣、生物底物和反义寡核苷酸。
- 批准号:
BB/V019848/1 - 财政年份:2021
- 资助金额:
$ 52.78万 - 项目类别:
Research Grant














{{item.name}}会员




